Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 200 participants.

Also called NCT03021928

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03021928
Other papers using this trial's data
  • Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial JAMA neurology, 2025-05-01 DOI, PubMed 40163159, PMC11959473 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03021928. Randomized; single masking; primary purpose prevention. Start 2017-06-14 (actual); primary completion 2023-08-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
Acronym
START
Condition
Stroke
Intervention (Other)
Time-To-Treatment Randomization
Lead sponsor
University of Texas at Austin (class: other)
Collaborator
Lone Star Stroke Research Consortium (class: not stated)
Collaborator
Texas Department of State Health Services (class: other)

Record details

Record id
cardio:ct-nct03021928
Content hash
5f2eeb499509346830f4143f52306d41d4c1182efce746f341ab39115998c52a